| 查看: 318 | 回复: 0 | |||
[交流]
Vivitrol和抑郁：病例报告及文献复习
|
|
The introduction of a long-acting depot formulation of naltrexone (Vivitrol), FDA approved for the treatment of alcohol and opioid dependence in 2006 and 2010, respectively, has raised safety concerns including: (1) risk of development or exacerbation of depressive symptoms during treatment; and (2) increased risk of opioid overdose after treatment cessation. The concern that treatment with long-acting naltrexone may lead to depressive symptoms has a plausible theoretical basis given the medication’s blockade of μ-opioid receptors, which, when activated, lead to positive mood states. Risk of depression and suicidality are listed as potential adverse reactions in the manufacturer’s insert and are commonly relayed to patients during informed consent for treatment (http://www.vivitrol.com/About/Safety). However, these concerns may not be substantiated. Given that depression is commonly comorbid with alcohol and opioid dependence, concerns about the exacerbation of depression could prevent many individuals from receiving beneficial treatment as more evidence emerges supporting the efficacy of depot naltrexone. A recent multisite randomized trial found that opioid-dependent subjects receiving long-acting naltrexone were far more likely to remain abstinent over 6 months of treatment (median of 90% abstinent weeks for naltrexone group vs. 35% for placebo group). In this paper, we review the existing literature on the effects of short-acting and long-acting naltrexone on mood as well as effects on preexisting depressive disorders, with the aim of assisting clinicians in selecting appropriate patients for treatment with this medication. provide：www.tianyuan520.com |
回复此楼» 本帖附件资源列表
-
欢迎监督和反馈：小木虫仅提供交流平台，不对该内容负责。
本内容由用户自主发布，如果其内容涉及到知识产权问题，其责任在于用户本人，如对版权有异议，请联系邮箱：xiaomuchong@tal.com - 附件 1 : 00132576-201409000-00007.pdf
2014-09-30 15:38:12, 99.98 K
» 猜你喜欢
AIE光敏剂-白灯功率密度的计算
已经有1人回复
-
医学学硕求调剂
已经有0人回复
-
呼吸系统论文润色/翻译怎么收费?
已经有283人回复
-
324求调剂
已经有0人回复
-
求调剂
已经有0人回复
-
杭州师范大学基础医学院免疫与病原生物学系-刘广宇课题组
已经有0人回复
-
杭州师范大学基础医学院研究生调剂招生火热来袭
已经有0人回复
-
0860生物医药/1053公共卫生-厦门大学少干计划专硕调剂；另有非全日制公卫专硕名额调剂
已经有0人回复
-
厦门大学国家重点实验室病原微生物与抗感染治疗课题组2026届博士招生
已经有0人回复